Immudex’s Post

𝐍𝐊 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐟𝐨𝐫 𝐓𝐮𝐦𝐨𝐮𝐫𝐬 𝐰𝐢𝐭𝐡 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐢𝐞𝐬 🧪 Like a laser-guided missile, scientists can use monoclonal antibodies to direct natural killer cells to cancer cells. ➡️ Unlike CD4+ and CD8+ cytotoxic T cells, NK cells express a unique "Fc receptor" called CD16A. This receptor enables NK cells to recognize a specific portion of antibodies and kill whatever it is that the antibody is bound to. Well, this seems pretty useless until you find out that our body will naturally coat foreign entities in antibodies, allowing NK cells to find and kill them. This phenomenon is referred to as "antibody-dependent cellular cytotoxicity", or ADCC, and is one of the major molecular characteristics that sets NK cells apart from T cells. 👉 When leveraged properly, NK-mediated ADCC can be an extremely POWERFUL anti-tumor force. Scientists have devised several combination approaches that co-administer an NK cell therapy with a tumor antigen-specific monoclonal antibody. These antibodies circulate to the tumor and coat the cancerous cells, which then directs the NK cell therapy - via their expression of CD16A - and greatly enhances the anti-tumor potency. 🙏 Special thanks to Jeffrey C. Martin, Ph.D. for collaborating with me on this one. Follow him for more oncological insights #celltherapy #oncology #immunotherapy #CGTweekly

Maxime Fredom et al. Impact of scFv on functionality and safety of third generation CD123 CAR T cells. Cancer Immunology Research, May 31,2024 https://lnkd.in/dea_fa_S "Abstract Chimeric antigen receptor (CAR) T cells express an extracellular domain consisting of a single-chain fragment variable (scFv) targeting a surface tumor–associated antigen. scFv selection should involve safety profiling with evaluation of the efficacy/toxicity balance, especially when the target antigen also is expressed on healthy cells. Here, to assess differences in terms of efficacy and on-target/off-tumor effects, we five different CARs targeting CD123 by substituting only the scFv. In in vitro models, T cells engineered to express three of these five CD123 CARs were effectively cytotoxic on leukemic cells without increasing lysis of monocytes or endothelial cells. Using the IncuCyte® system, we confirmed the low cytotoxicity of CD123 CAR T cells on endothelial cells. Hematotoxicity evaluation using progenitor culture and CD34 cell lysis showed that two of the five CD123 CAR T cells were less cytotoxic on hematopoietic stem cells. Using a humanized mouse model, we confirmed that CD123– cells were not eliminated by the CD123 CAR T cells. Two CD123 CAR T cells reduced tumor infiltration and increased overall survival of mice in three in vivo models of blastic plasmacytoid dendritic cell neoplasm. In an aggressive version of this model, bulk RNA sequencing analysis showed that these CD123 CAR T cells upregulated genes associated with cytotoxicity and activation/exhaustion a few days after the injection. Together, these results emphasize the importance of screening different scFvs for the development of CAR constructs to support selection of cells with the optimal risk–benefit ratio for clinical development.".

By driving immune cells toward suppressive functions, cancer cells have a better chance of survival. This increase in the number of suppressive cells, like myeloid derived suppressor cells and regulatory T cells, creates an environment where the tumor can grow undetected. Characterizing these cell phenotypes in cancer can aid in our understanding of these important tumor immune cell interactions. Find antibodies recognizing these immune suppressive cell markers and other important oncology biomarkers from Bethyl. #immunooncology #immuneresponse #cancer #cancerresearch #cancerbiology #oncology #oncologyresearch #precisionresearch #discoveries #science #antibodyresearch #monoclonalantibodies #polyclonalantibodies #antibodyvalidation #labreagents #biotechsolutions https://lnkd.in/gyay2XVE

Liver metastasis site in pancreatic cancer contains cellular populations, such as RGS5+ cancer-associated fibroblasts aiding tumor growth, CCL18+ lipid-associated macrophages with immunosuppressive functions, S100A8+ neutrophils, and FOXP3+ regulatory T cells, which hinder immune attack. These results were observed by analyzing pancreatic cancer tissues from primary tumors and liver metastases using single-cell RNA sequencing. The study reveals the complex microenvironment of metastatic pancreatic cancer and identifies potential targets for tailored therapies. A noteworthy study by Shu Zhang et al. on Nature Communications “Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis” #pancreaticcancer #cancermetastasis #scRNA #singlecell #BioTuring Read the publication here: https://lnkd.in/gQzqqQfG Explore the dataset on Talk2Data now: https://lnkd.in/geXYPPNk

#cellmorphology #apoptosis #breastcancer #cellproliferation "Spinosyn A exerts anti-tumorigenic effects on progesterone-sensitive ERα-positive breast cancer cells by modulating multiple signaling pathways" #mondayread 🔍📄 https://bit.ly/3SA0DSv 🔬 The authors used HoloMonitor M4 to monitor the effects of Spinosyn A on breast cancer cells with cell morphology and proliferation, providing valuable insights into the mechanisms underlying the anti-tumorigenic effects of Spinosyn A. ABOUT this #publication The paper describes the effects of Spinosyn A, a natural insecticide, on breast cancer cells. The study found that Spinosyn A has anti-tumorigenic effects on progesterone-sensitive ERα-positive breast cancer cells by modulating multiple signaling pathways. The authors of the study used various techniques to investigate the effects of Spinosyn A on breast cancer cells, including cell viability assays, western blotting, and qPCR. They found that Spinosyn A inhibits the growth of breast cancer cells by inducing apoptosis and cell cycle arrest. Additionally, Spinosyn A was found to modulate multiple signaling pathways, including the PI3K/Akt/mTOR pathway, the MAPK/ERK pathway, and the JAK/STAT pathway. #holomonitor #QPI

🌟 Unlocking the Power of Antibodies in the Fight Against Kidney Cancer! 🌐💪 Did you know that antibodies play a crucial role in targeting specific proteins associated with kidney cancer? 🎯 In the realm of Renal Cell Carcinoma (RCC), SDHB, C3D, and more, these tiny warriors are making a big impact! 🔬 Understanding RCC: Renal Cell Carcinoma is a formidable opponent, but antibodies are the superheroes of precision medicine, zeroing in on cancer cells and sparing healthy ones. 🦸♂️🔍 🎯 Targeting SDHB: SDHB mutations are common in kidney cancer. Antibodies are like precision-guided missiles, recognizing and neutralizing SDHB, disrupting cancer's plans. 💥💊 🛡️ Guardians Against C3D: The complement system, specifically C3D, can fuel the growth of RCC. Antibodies act as shields, intercepting and neutralizing C3D to halt the cancerous progression. 🚫🦠 🤝 Let's unite in raising awareness about the pivotal role antibodies play in the battle against kidney cancer! Share this post to spread the word about the cutting-edge science and breakthroughs in personalized medicine. 💙🌍 #KidneyCancerAwareness #Antibodies #PrecisionMedicine #RCC #SDHB #C3D #CancerResearch #MedicalBreakthroughs #HealthHeroes

🚀 What are The Cytokine and Chemokine Targeting Strategies in Tumor Treatment?🌟 In the fight against cancer, innovative approaches are crucial. Recent insights highlight various methods to modify cytokine and chemokine signaling pathways: ✅ Blocking Protumor Cytokine Signaling: Strategies include antibodies, traps, inhibitors, antisense oligonucleotides (ASOs), and vaccines to disrupt harmful signaling. ✅ Activating Antitumor Cytokines: Techniques like direct administration, electroporation, immunocytokines, and viral vectors aim to enhance immune responses and combat tumors effectively. ✅ Chemokine Signaling: Targeting protumor chemokines can reduce immune evasion and tumor growth, while engineering T cells and using oncolytic viruses can boost antitumor responses. 🔗 https://lnkd.in/gfgYNt7h Let’s continue to innovate and collaborate in the quest for better cancer therapies! 👏 MedChemExpress (MCE) provides a range of cytokines and growth factors, including interleukins, chemokines, interferons, transforming growth factors, fibroblast growth factors, as well as the cytokine receptor family. 👉 For more detailed information: https://lnkd.in/d4WJE_G #Cancer #Immunotherapy #Cytokines #Chemokines #Oncology #biotechnology

A signaling molecule in neuroblastoma immunosuppression and aggressiveness identified! The MYCN oncoprotein (proteins related to the growth of cancer cells) plays a key role in starting, advancing and making it difficult to treat various human cancers. When MYCN is overactive, especially in high-risk neuroblastoma (childhood cancer often found in the adrenal glands), the tumors become less responsive to immunotherapy—a treatment that uses the body's immune system to fight cancer. Still, recognition of this problem has not led to any effective strategies to tackle this problem. In a new study, researchers found that MYCN selectively increases the levels of a signaling molecule, CKLF, in neuroblastoma cells to suppress anti-tumor immune responses and promote tumor aggressiveness. The authors demonstrated that as early as the premalignant stage, tumor cells secrete CKLF to attract CCR4-expressing CD4+ cells, inducing immunosuppression and tumor aggression. Genetic depletion of CD4+ T regulatory cells abolishes the immunorestrictive and protumorigenic effects of CKLF. #ScienceMission #sciencenewshighlights https://lnkd.in/dwta6px9

𝗜𝗺𝗺𝘂𝗻𝗼𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝘀𝗺, 𝘀𝗶𝗴𝗻𝗮𝗹𝗶𝗻𝗴 𝗮𝗻𝗱 𝗶𝗺𝗺𝘂𝗻𝗲 𝗰𝗵𝗲𝗰𝗸𝗽𝗼𝗶𝗻𝘁𝘀: 𝘁𝗮𝗿𝗴𝗲𝘁𝘀 𝗳𝗼𝗿 𝗰𝗮𝗻𝗰𝗲𝗿 𝗶𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 Immunometabolism has garnered a lot of attention for its role in cancer and as potential therapeutic targets. This review discusses changes in the metabolism of tumor cells and immune cells, as well as the interaction between metabolis and signaling pathways, as well as metabolic immune checkpoints. All of it in the context of their potential as therapeutic targets and/or their role in affecting responses to immunotherapy. https://lnkd.in/dTBhwR3h Full publication: Su, R., Shao, Y., Huang, M. et al. Immunometabolism in cancer: basic mechanisms and new targeting strategy. Cell Death Discov. 10, 236 (2024). https://lnkd.in/djnbWyfs. Freely available under a Creative Commons license: https://lnkd.in/dyuva2r8 #science #metabolism #immunology #oncology